Combined oral contraceptive pill use associated with reduced dysglycemia risk for women with PCOS<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 22, 2021 (HealthDay News) — Women with polycystic ovary syndrome (PCOS) have an increased risk for dysglycemia in all body mass index (BMI) subgroups, and combined oral contraceptive pill (COCP) use is associated with a reduced dysglycemia risk, according to a study published online Oct. 14 in Diabetes Care<\/em>.<\/p>\n Balachandran Kumarendran, M.B.B.S., from the University of Birmingham in the United Kingdom, and colleagues conducted a retrospective population-based cohort study to examine dysglycemia risk among 64,051 women with PCOS and 123,545 matched controls and a nested pharmacoepidemiological case-control study to examine COCP use in relation to the risk for dysglycemia (2,407 women with PCOS with and without a diagnosis of dysglycemia during follow-up [cases and controls]).<\/p>\n The researchers found that after adjustment for age, social deprivation, BMI, ethnicity, and smoking, the hazard ratio for dysglycemia was 1.87 for women with PCOS; the rates of dysglycemia were increased in all BMI subgroups. Reduced dysglycemia risk was seen for women with PCOS and COCP use (adjusted odds ratio, 0.72).<\/p>\n “Women with PCOS have a significantly increased risk of dysglycemia that persisted after adjustment for BMI, corroborating the recommendation that women with PCOS should be systematically screened for type 2 diabetes irrespective of body weight category,” the authors write. “In our nested pharmacoepidemiology study, we found that women with PCOS and exposure to COCPs had a lower risk of incident dysglycemia.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n